Hib conjugate vaccine - Chengdu Olymvax Biopharmaceuticals
Alternative Names: Haemophilus influenzae type b conjugate vaccine - Chengdu Olymvax BiopharmaceuticalsLatest Information Update: 04 Oct 2019
At a glance
- Originator Chengdu Olymvax Biopharmaceuticals
- Developer Chengdu Olymvax Biopharmaceuticals; Jiangsu Provincial Center for Disease Control and Prevention
- Class Conjugate vaccines; Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilus infections
Most Recent Events
- 04 Oct 2019 Discontinued - Phase-III for Haemophilus infections (In children, In infants, Prevention) in China (IM)